Summary
This prediction ended on 12.07.25 with a price of €7.01. The price of Evotec SE decreased from the start of the prediction. Compared to the start price this resulted in a performance of -23.18%. This prediction was marked as speculative and is excluded from kostojunior's performance statistics.Evotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Evotec SE | -4.205% | -4.205% | -37.470% |
| iShares Core DAX® | 0.734% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -2.686% | -0.146% | 3.810% |
| iShares Nikkei 225® | -2.261% | -2.729% | 11.679% |
| iShares S&P 500 | -1.346% | 0.467% | 1.970% |
According to kostojunior what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Cons
Dependend from some customers or products
Sustainability is little important
high free float
Higher risks for its business
Growths slower than the competition
Low dividend yield expected
negative Cash Flow expected
Bad rating
Little Investments for future growth
Comments by kostojunior for this prediction
In the thread Evotec AG diskutieren
Sell Evotec SE
In the thread Trading Evotec AG
Die von kostojunior gewählte maximale Laufzeit wurde überschritten